

# Once-weekly dulaglutide ups glycemic control in youth with T2D

8 June 2022



For youth with type 2 diabetes, dulaglutide is superior to placebo for reducing mean glycosylated hemoglobin level, according to a study published online June 4 in the *New England Journal of Medicine* to coincide with the annual meeting of the American Diabetes Association, held from June 3 to 7 in New Orleans.

Silva A. Arslanian, M.D., from the University of Pittsburgh School of Medicine, and colleagues conducted a double-blind, placebo-controlled 26-week trial involving 154 participants (aged 10 to 85th percentile) being treated with lifestyle modifications alone or with [metformin](#) with or without basal insulin who were randomly assigned to receive once-weekly subcutaneous injections of placebo, dulaglutide 0.75 mg, or dulaglutide 1.5 mg. Participants were then included in a 26-week open-label extension, and those who had received placebo were switched to dulaglutide 0.75 mg.

The researchers found that at 26 weeks, the mean glycosylated hemoglobin level increased in the [placebo](#)

[group](#) (0.6 percentage points) and decreased in the dulaglutide groups (?0.6 and ?0.9 percentage points in the 0.75-mg and 1.5-mg groups, respectively). A higher percentage of participants in the pooled dulaglutide groups had a glycosylated hemoglobin level of less than 7.0 percent than in the placebo group at 26 weeks (51 versus 14 percent). In the placebo group, fasting glucose concentration increased (17.1 mg/dL), while in the pooled dulaglutide groups, there was a decrease (?18.9 mg/dL); no between-group differences were seen in the change in BMI.

"Among youths with inadequately controlled type 2 diabetes being treated with or without metformin or [basal insulin](#), once-weekly treatment with dulaglutide was superior to placebo in improving [glycemic control](#)," the authors write.

Several authors disclosed financial ties to [pharmaceutical companies](#), including Eli Lilly, which manufactures dulaglutide and funded the study.

**More information:** Silva A. Arslanian et al, Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes, *New England Journal of Medicine* (2022). [DOI: 10.1056/NEJMoa2204601](https://doi.org/10.1056/NEJMoa2204601)

[Annual meeting of the American Diabetes Association](#)

© 2022 [HealthDay](#). All rights reserved.

APA citation: Once-weekly dulaglutide ups glycemic control in youth with T2D (2022, June 8) retrieved 12 November 2022 from <https://medicalxpress.com/news/2022-06-once-weekly-dulaglutide-ups-glycemic-youth.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*